\n
\n Bio
\n
“Exploring the Potentials of Selective Blocking of the IL-1 S
ystem by Distinct Targeting of the Co-receptor TILRR”
\n
p>\n
Dr. Qwarnstrom’s research focuses on regulation of receptor functio
n and cell signalling. Work on signal transduction\, has centred on regula
tion of NF-B pathways and on using single cell recordings of regulatory e
vents in live cells. The single cell data was used as the basis for develo
ping highly detailed\, predictive models of the IL-1 system and the NF-B
network. Interdisciplinary projects led to identification and characterisa
tion of the IL-1R1 co-receptor TILRR and established its role in IL-1 rece
ptor function\, NF-B regulation and disease. Ongoing work focuses on eval
uating TILRR as a potential therapeutic target.
\n
\n
To join
the live event please request the link by emailing: icm@jhu.edu
\n
\n
▶RECORDING
\n
\n
\n Abs
tract
\n
\n
“Exploring the Potentials of Sel
ective Blocking of the IL-1 System by Distinct Targeting of the Co-recepto
r TILRR”
\n
\n
\n
\n
\n
Aberrant activation of NF-B plays a central
role in disease. IL-1 is a key regulator of NF-B and has emerged as a rat
ional therapeutic target. Clinical trials have demonstrated that nonselect
ive blocking of the IL-1 system can cause serious side effects related to
impairment of the immune system\, highlighting the need for more specific
targeting. Our interdisciplinary studies on regulation of NF-B led to ide
ntification of the IL1R1 coreceptor TILRR and established its role in cont
rolling IL1R1 function and in driving aberrant activation of NF-B. Our pu
blished work shows that genetic deletion or antibody blocking of TILRR red
uces progression of inflammatory conditions. Pathway enrichment analysis o
f TILRR-induced gene expression profiles has revealed significant links wi
th NF-B signalling\, Alzheimer’s disease and cancer. I will describe the
predictive modelling approaches used in these studies\, outline the key re
gulatory events that underpin TILRR’s control of the IL-1 system and selec
tive regulation the NF-B pathways\, present recent data on the role of TI
LRR in disease and discuss its potential as a therapeutic target.
\n
\n
\n
▶RECORDING
\n
\n